

The Clinical Spectrum of Mutations in L1, a Neuronal Cell Adhesion Molecule

Erik Fransen, Lieve Vits, Guy Van Camp, and Patrick J. Willems

Department of Medical Genetics, University of Antwerp, Antwerp, Belgium

Mutations in the gene encoding the neuronal cell adhesion molecule L1 are responsible for several syndromes with clinical overlap, including X-linked hydrocephalus (XLH, HSAS), MASA (mental retardation, aphasia, shuffling gait, adducted thumbs) syndrome, complicated X-linked spastic paraplegia (SP 1), X-linked mental retardation-clasped thumb (MR-CT) syndrome, and some forms of X-linked agenesis of the corpus callosum (ACC). We review 34 L1 mutations in patients with these phenotypes.

© 1996 Wiley-Liss, Inc.

KEY WORDS: L1, hydrocephalus, MASA, mental retardation, neural cell adhesion

L1 AND ASSOCIATED DISEASES

X-linked hydrocephalus (HSAS: hydrocephalus due to stenosis of the aqueduct of Sylvius) described by Bickers and Adams in 1949 and MASA (mental retardation, aphasia, shuffling gait, adducted thumbs) syndrome described by Bianchine and Lewis in 1974 are 2 X-linked neuronal disorders with an overlapping clinical spectrum. Because linkage analysis showed that both disease loci are localized in Xq28 [Winter et al., 1989; Willems et al., 1990], we suggested L1 as a possible candidate gene for both disorders [Willems et al., 1992]. The L1 (L1CAM) gene is located in Xq28 and encodes a neuronal cell adhesion molecule known to play an important role in the development of the nervous system. L1 mutation studies have confirmed this hypothesis because several L1 mutations were found in families with HSAS and MASA syndrome [Rosenthal et al., 1992; Jouet et al., 1993, 1994, 1995; Van Camp et al., 1993; Coucke et al., 1994; Forrest et al., 1994; Fransen et al., 1994, 1995; Vits et al., 1994; Jouet and Kenwrick, 1995]. In addition, L1 mutations were found

in families with complicated spastic paraplegia (SP1) [Jouet et al., 1994] and complicated corpus callosum agenesis/dysgenesis (ACC/DCC) [Vits et al., 1994], each family presenting with a MASA-like phenotype. Apart from these molecular studies, clinical studies have indicated the large overlap in the phenotype of the 4 conditions and the presence of several of these phenotypes in a single family [Schrandt-Stumpel et al., 1990, 1995; Fryns et al., 1991; Willems et al., 1992]. This proved that HSAS, MASA, complicated SP1, and complicated ACC/DCC are not separate conditions but rather represent overlapping clinical spectra due to mutations in a single gene, L1 (Fig. 1). Therefore, a nosologic separation between those disorders no longer makes sense. Because the most typical and frequent symptoms caused by L1 mutations include corpus callosum agenesis, mental retardation, adducted thumbs, spastic paraplegia, and hydrocephalus, we have referred to this clinical spectrum as the CRASH syndrome [Fransen et al., 1995] (Table I).

L1, also referred to as L1CAM (L1 cell adhesion molecule) is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It consists of various domains, including 6 immunoglobulin and 5 fibronectin type III domains in the extracellular part, 1 transmembrane segment, and a cytoplasmic domain (Fig. 2). Expression is restricted mainly to the axons of outgrowing nerve cells in the central (CNS) and peripheral (PNS) nervous systems and on Schwann cells in the PNS, suggesting a key role in the axon outgrowth and pathfinding during embryonic development (Table II). Interactions with the cellular environment occur via homophilic interactions with itself and via heterophilic interactions with axonin-1 (TAG-1), F3 (F11), and phosphocan [Lemmon et al., 1989]. At least a part of the signal transduction appears to occur through activation with fibroblast growth factor receptors (FGFR) [Williams et al., 1994]. L1 most likely interacts with FGFRs through a motif of 5 amino acids between immunoglobulin domains 3 and 4. This domain is present in all 4 FGFR genes and is called the CAM-homology domain (CHD).

The L1 gene spans 16 Kb and contains 28 exons, encoding 1,256 amino acids (Table II). The availability of the complete genomic sequence with the intron–exon boundaries (A. Rosenthal, personal communication) has facilitated exon-by-exon mutation analysis.

Received for publication October 20, 1995; revision received January 11, 1996.

Address reprint requests to Prof. Patrick Willems, Department of Medical Genetics, University of Antwerp, 2610 Antwerp, Belgium.




Fig. 1. Schematic representation of the overlapping clinical spectra of HSAS, MASA syndrome, complicated SP1, and complicated ACC/DCC.

L1 MUTATIONS

In this paper we describe 7 new mutations and review 27 previously reported mutations [Rosenthal et al., 1992; Van Camp et al., 1993; Jouet et al., 1993, 1994, 1995; Coucke et al., 1994; Forrest et al., 1994; Fransen et al., 1994, 1995; Vits et al., 1994; Jouet and Kenwick, 1995]. All mutations are described in Table IV and depicted in Figure 3. In many families with HSAS and MASA and in 1 SP1 and 1 ACC/DCC family, an L1 mutation has been identified. These mutations are dispersed over the whole L1 gene: in each structural L1 domain, except for fibronectin III domain 1 and CHD, 1 or more mutations have been found.

The spectrum of mutations shows a wide variety, with gross rearrangements such as large deletions or duplications, small (1–5 bp) deletions or insertions, missense and nonsense mutations, splice site mutations, and a unique and novel type of mutation that destroys a splicing branch point signal [Rosenthal et al., 1992] (Table III). The mutations can be classified into 2 groups. The first group (class I) consists of mutations that disrupt the overall structure of L1 by a nonsense mutation, a splice site mutation, a frameshift mutation caused by a small deletion or insertion, or a larger rearrangement. Approximately half of the currently known L1 mutations belong to this group. The other mutations (class II) are missense mutations. These mutations leave the overall structure of L1 intact in that

TABLE I. Different Designations of Conditions Due to Mutations in L1

HSAS	Hydrocephalus, stenosis of aqueduct of Sylvius
XLH	X-linked hydrocephalus
MASA	Mental retardation, aphasia, shuffling gait, adducted thumbs
MR-CT	Mental retardation–clapsed thumbs
ACC-DCC	Agenesis corpus callosum–dysgenesis corpus callosum
SP1	Complicated spastic paraparesis, type 1
CRASH	Corpus callosum agenesis, retardation, adducted thumbs, spastic paraparesis, hydrocephalus




Fig. 2. Model of L1 with its different functional domains.

only a single amino acid is replaced for another (Fig. 3). Class I mutations give rise to a truncated L1 protein if normal transcription, translation, and protein stability are maintained. If the protein is truncated in the extracellular domain, the transmembrane domain is lost, and no L1 can be expressed on the membrane, leading to loss of all functions of L1. If the protein is truncated in the intracellular domain, L1 might still be present on the membrane, and most likely only the intracellular function of L1 is impaired. L1 with class II missense mutations most likely will be present on the cell membrane. However, one of the different functions of L1 will be impaired by the amino acid substitution. If the missense mutation is present in one of the extracellular domains, the binding capacity of L1 with one of its ligands may be disrupted. In vitro constructs with these muta-

TABLE II. Structure and Function of L1

Structure	Function
Gene: 28 exons (± 16 kb)	Migration of neurons
mRNA: 5.5 kb	Outgrowth of neurites
ORF: 1,256 amino acids	Fasciculation of neurites
MW: 142 kDa	Ca ²⁺ influx
Domains	Interaction: neuron to neuron, neuron to glial cell
1 Signal sequence (35 AA)	Heterophilic interaction with axonin-1 and NCAM
6 Immunoglobulin domains (579 AA)	Homophilic interaction with itself
5 Fibronectin III domains (499 AA)	Interaction with FGFR
1 Transmembrane domain (30 AA)	
1 Cytoplasmic domain (113 AA)	
Multiple glycosylation sites (Asn-X-Ser/Thr)	
Multiple phosphorylation sites (Thr and Ser)	
1 RGD sequence (Arg-Gly-Asp)	




Fig. 3. Genomic structure of the L1 gene. Exons are drawn as boxes, introns as lines. The lengths of all introns and exons 2 (15 bp) and 27 (12 bp) are not drawn to scale. The mutations, numbered according to Table IV, are indicated by vertical arrows. Arrows with a dot represent missense mutations; arrows without a dot represent mutations disrupting the overall L1 structure (stop codon mutations, splice site mutations, frameshift mutations, or large rearrangements).

tions may be used for in vitro studies to elucidate the interactions between L1 and its ligands and the functional L1 domains involved in this binding.

Only 2 mutations in more than 60 families studied in our laboratory can be detected by Southern blot analysis. Therefore, mutation analysis in nearly all families is based on more sensitive diagnostic methods such as exon-by-exon scanning by SSCP or sequencing. However, this is a laborious and time-consuming task because 28 exons have to be investigated.

GENOTYPE-PHENOTYPE CORRELATION

Of the 26 mutations found in families with a severe phenotype (HSAS), 16 belong to class I (mutations dis-

rupting the overall L1 structure) and 10 to class II (missense mutations). In the 8 families with a milder phenotype (MASA, SP1, ACC) 2 have class I mutations and 6 have class II mutations. Although this suggests that mutations disrupting the overall L1 structure more often result in a more severe clinical phenotype including hydrocephalus, this genotype-phenotype correlation is weak. Analysis of the 34 mutations compiled in this paper (Table IV) indicates that different mutations in the same structural domain may lead to different clinical phenotypes. Furthermore, in some cases, the same mutation can lead to different phenotypes within the same family [Schrandt-Stumpel et al., 1990, 1995; Fryns et al., 1991; Willems et al., 1992]. In conclusion, it is impossible to predict the severity of symptoms by identification of the L1 mutation.

ACKNOWLEDGMENTS

We are indebted to R. Bernaerts, N. Aerts, and K. De-necker for secretarial assistance, A. Rosenthal for the L1 sequence information prior to publication, and M. Sagi, P. Deleu, L. Fry-Mehltreter, R. Röhrborn, R. Szibor, S. Lyonnet, A. Munnich, Z. Papp, and E. Wesby for referral of patients. This study was supported in part by grants from the Belgian NFWO (National Fund for Scientific Research) and the Association Française contre les Myopathies to P.J.W. and con-

TABLE III. Different Types of L1 Mutations in CRASH Syndrome

Large deletion	1
Large duplication	1
Small deletion	5
Small insertion	1
Missense mutation	16
Nonsense mutation	2
Splice site	6
Branch point signal	1
Unknown mutation	1
Total number of mutations	34

TABLE IV. Overview of L1 Mutations*

No.	Exon/intron	Domain	Nucleotide	Consequence	Type	Ethnic origin	Disease	Reference
1	E 1	Signal. pept.	G26→C	W9S	Missense		HSAS	Jouet et al., 1995
2	I 1	Signal. pept.	76 g+1→t	?	Splice site		HSAS	Jouet and Kenrick, 1995
3	E 4	Ig 1	G361→A	G121S	Missense		HSAS	Jouet et al., 1995
4	I 4	Ig 1	400 g+5→a	FS 108	Splice site	France	HSAS	Coucke et al., 1994
5	E 6	Ig 2	T536→G	I179S	Missense	Belgium	MASA	Ruiz et al., 1995
6	E 6	Ig 2	C550→T	R184W	Missense	Belgium	HSAS	This study
7	E 6	Ig 2	G551→A	H210Q	Missense	UK	HSAS	Jouet et al., 1994
8	E 6	Ig 2	C630→G	FS 215	Missense	USA	MASA	Vits et al., 1994; Jouet et al., 1994
9	E 6	Ig 2	664 del G	FS 239	Deletion 1 bp	Germany	HSAS	This study
10	E 7	Ig 3	711 ins AGAC	FS 239	Insertion 4 bp	Canada	HSAS	This study
11	E 7	Ig 3	G791→A	C264Y	Missense		HSAS	Jouet et al., 1993
12	E 8	Ig 3	G925→A	E309K	Missense		MASA	Jouet et al., 1995
13	E 9	Ig 4	G1108→A	G370R	Missense	USA	MASA	Ruiz et al., 1995
14	E 10	Ig 4	T1172→C	L391P	Missense	France	HSAS	This study
15	E 10	Ig 4	1248 del T	FS 416	Deletion 1 bp	Hungary	HSAS	This study
16	I 10	Ig 4	1267 g+1→a	skipping exon 10	Splice site		HSAS	Forrest et al., 1994
17	I 10	Ig 4	1267 g+1→a	?	Splice site	Germany	HSAS	This study
18	I 10	Ig 4	1267 a+4→t	Skipping exon 10	Splice site		HSAS	Jouet et al., 1995
19	E 11	Ig 5	G1354→A	G452R	Missense		HSAS	Jouet et al., 1994
20	E 12	Ig 5	C1453→T	R485Stop	Nonsense		HSAS	Jouet et al., 1994
21	E 14	Ig 6	C1756→T	Q586Stop	Nonsense		HSAS	Jouet et al., 1995
22	E 14	Ig 6	1780 del A	FS 594	Deletion 1 bp		HSAS	Jouet et al., 1994
23	E 14	Ig 6	G1792→A	D598N	Missense	U.S.A.	HSAS	This study
24	E 18	Fn 2	G2302→T	V768F	Missense	USA	MASA	Vits et al., 1994
25	I 18	Fn 2	2432 a-19→c	(1) 811 ins 23 AA (2) Skipping exon 19	Branch point		HSAS	Jouet et al., 1995
26	E 21	Fn 4	?	Skipping exon 21	?		HSAS	Rosenthal et al., 1992
27	E 21	Fn 4	C2822→T	P941L	Missense		HSAS	Forrest et al., 1994
28	E 22	Fn 4	2884 del G	FS 962	Deletion 1 bp		HSAS	Jouet et al., 1995
29	E 24	Fn 5	A3209→G	Y1070C	Missense		HSAS	Jouet et al., 1994
30	E 26	Cytopl.	3489 del TG	FS 1164	Deletion 2 bp		HSAS	Jouet et al., 1995
31	I 26	Cytopl.	3531 g-12→a	?	Splice site		MASA	Jouet et al., 1994
32	I 27→28	Cytopl.	3543 del→?	del 1181→end	Deletion 2 kb	Mexico	MASA	Vits et al., 1994
33	I 27→E 28	Cytopl.	3543 dpl 125	FS 1223	duplication 1.3 kb	The Netherlands	HSAS	Van Camp et al., 1993
34	E 28	Cytopl.	C3581→T	S1194L	Missense	The Netherlands	MASA	Fransen et al., 1994

* An updated table of L1 mutations is available electronically through the world wide web at the L1 Mutation Homepage (<http://alt-www.uia.ac.be/udnalab/l1.html>). At this site, a table with every published and many unpublished L1 mutations is maintained, and useful information such as L1 sequences for various organisms, L1 exon structure, L1 domain structure, addresses, and references is listed.

certed action from the University of Antwerp to G.V.C. and P.J.W. E.F. holds a scholarship from the I.W.T. (Institute for the Support of Research in Science and Technology).

REFERENCES

- Bianchine JW, Lewis RC (1974): The MASA syndrome: A new hereditary mental retardation syndrome. *Clin Genet* 5:298–306.
- Bickers DS, Adams RD (1949): Hereditary stenosis of the aqueduct of Sylvius as a cause of congenital hydrocephalus. *Brain* 72:246–262.
- Coucke P, Vits L, Van Camp G, Serville F, Lyonnet S, Kenwrick S, Rosenthal A, Wehnert M, Munnich A, Willems PJ (1994): Identification of a 5' splice site mutation in intron 4 of the L1CAM gene in an X-linked hydrocephalus family. *Hum Mol Genet* 3:671–673.
- Forrest SM, Rosenthal A, Balnaves ME (1994): Mutation detection in X-linked hydrocephalus. *Am J Hum Genet* 55:A219.
- Fransen E, Schrandt-Stumpel C, Vits L, Coucke P, Van Camp G, Willems PJ (1994): X-linked hydrocephalus and MASA syndrome present in one family are due to a single missense mutation in exon 28 of the L1CAM gene. *Hum Mol Genet* 3:2255–2256.
- Fransen E, Lemmon V, Van Camp G, Vits L, Coucke P, Willems PJ (1995): Crash syndrome: A clinical spectrum of corpus callosum hypoplasia, retardation, adducted thumbs, spastic paraparesis and hydrocephalus due to mutations in one single gene, L1. *Eur J Hum Genet* 3:273–284.
- Fryns JP, Spaepen A, Cassiman J-J, Van den Berghe H: X-linked complicated spastic paraplegia, MASA syndrome and X-linked hydrocephaly due to congenital stenosis of the aqueduct of Sylvius: A variable expression of the same mutation at Xq28. *J Med Genet* 28:429–431.
- Jouet M, Kenwrick S (1995): Gene analysis of L1 neural cell adhesion molecule in prenatal diagnosis of hydrocephalus. *Lancet* 345:161–162.
- Jouet M, Rosenthal A, Macfarlane J, Kenwrick S, Donnai D (1993): A missense mutation confirms the L1 defect in X-linked hydrocephalus. *Nature Genet* 4:331.
- Jouet M, Rosenthal A, Armstrong G, Macfarlane J, Stevenson R, Paterson J, Matzenberg A, Ionanescu V, Temple K, Kenwrick S (1994): X-linked spastic paraplegia (SPG 1), MASA syndrome and X-linked hydrocephalus result from mutations in the L1 gene. *Nature Genet* 7:402–407.
- Jouet M, Moncla A, Paterson J, McKeown C, Fryer A, Carpenter N, Holmberg E, Wadelius C, Kenwrick S (1995): New domains of neural cell-adhesion molecule L1 implicated in X-linked hydrocephalus and MASA syndrome. *Am J Hum Genet* 56:1304–1314.
- Lemmon V, Farr KL, Lagenaur C (1989): L1-mediated axon outgrowth occurs via a homophilic binding mechanism. *Neuron* 2:1597–1603.
- Rosenthal A, Jouet M, Kenwrick S (1992): Aberrant splicing of neural cell adhesion molecule L1 mRNA in a family with X-linked hydrocephalus. *Nature Genet* 2:107–112.
- Ruiz JC, Cuppens H, Legius E, Fryns JP, Glover T, Marynen P, Cassiman JJ (1995): Mutations in L1-CAM in two families with X-linked complicated spastic paraplegia, MASA syndrome, and HSAS. *J Med Genet* 32:549–552.
- Schrander-Stumpel C, Legius E, Fryns JP, Cassiman JJ (1990): MASA syndrome: New clinical features and linkage analysis using DNA probes. *J Med Genet* 27:688–692.
- Schrander-Stumpel C, Höweler C, Jones M, Sommer A, Stevens C, Tinschert S, Israel J, Fryns JP (1995): The spectrum of X-linked hydrocephalus (HSAS), MASA syndrome, and complicated spastic paraplegia (SPG1): Clinical review with six additional families. *Am J Med Genet* 56:1–8.
- Van Camp G, Vits L, Coucke P, Lyonnet S, Schrandt-Stumpel C, Darby J, Holden J, Munnich A, Willems PJ (1993): A duplication in the L1CAM gene associated with X-linked hydrocephalus. *Nature Genet* 4:421–425.
- Vits L, Van Camp G, Coucke P, Wilson G, Schrandt-Stumpel C, Schwarz C, Willems PJ (1994): MASA syndrome is due to mutations in the L1CAM gene. *Nature Genet* 7:408–413.
- Willems PJ, Dijkstra I, Van der Auwera BJ, Vits L, Coucke P, Raeymakers P, Van Broeckhoven C, Consalez GG, Freeman SB, Warren ST, Brouwer OF, Brunner HG, Renier WO, Van Elsen AF, Dumon JE (1990): Assignment of X-linked hydrocephalus to Xq28 by linkage analysis. *Genomics* 8:367–370.
- Willems PJ, Vits L, Raeymakers P, Beuten J, Coucke C, Holden JJ, Van Broeckhoven C, Warren ST, Sagi M, Robinson D, Dennis N, Friedman KS, Magnay D, Lyonnet S, White BN, Wittwer BH, Aylsworth AS, Reicke S (1992): Further localization of X-linked hydrocephalus in the chromosomal region Xq28. *Am J Hum Genet* 51:307–315.
- Williams EJ, Furness J, Walsh FS, Doherty P (1994): Activation of the FGF receptor underlies neurite outgrowth stimulated by L1, N-CAM and n-cadherin. *Neuron* 13:583–594.
- Winter RM, Davies KE, Bell MV, Huson SM, Patterson MN (1989): MASA syndrome: Further clinical delineation and chromosomal location. *Hum Genet* 82:367–370.